Norroy Bioscience
Norroy Bioscience is a China-based radiopharmaceutical company that leads 3 cancer trials in OnCo, testing the PSMA-targeted radiopharmaceuticals 177Lu-NYM032 and 68Ga-NYM032 in prostate cancer.
Overview
Norroy Bioscience is a clinical-stage company developing therapeutic and diagnostic radiopharmaceuticals together with automated synthesis systems for their manufacture. Its candidates are led by PSMA-targeted 177Lu-NYM032 and 68Ga-NYM032 in prostate cancer and CAIX-targeted tracers in kidney cancer. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo (2 in phase 3 or 2/3): NCT06383052 (phase 1/2, A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC), NCT07615101 (phase 3, Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in...) and NCT07649122 (phase 3, This Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imagin...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.